Abstract 5-formylcytosine (5fC) is a rare base found in mammalian DNA and thought to be involved in active DNA demethylation. Here, we show that developmental dynamics of 5fC levels in mouse DNA differ from those of 5-hydroxymethylcytosine (5hmC), and using stable isotope labelling in vivo, we show that 5fC can be a stable DNA modification. These results suggest 5fC has functional roles in DNA that go beyond being a demethylation intermediate.
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DNA of all mammalian cells and tissues is methylated at specific loci, mainly in the 5'-cytosine-phosphate-guanine-3' (CpG) context, to modulate the expression of genes 1 . 5-methylcytosine (5mC) is produced from cytosine (C) by dedicated DNA methyltransferases using S-adenosylmethionine (SAM) as a source of the methyl group 2 . In 2009, two independent laboratories found 5-hydroxymethylcytosine (5hmC) to be present in mammalian DNA and to be the product of ten eleven translocation (TET)-enzyme mediated oxidation of 5mC 3, 4 . This oxidised base occurs in all mammalian cells and tissues with global levels ranging between 0.005% and 0.7% of all cytosines 5, 6 . The iron(II) and 2-oxoglutarate dependent TET enzymes can also oxidise 5hmC further to 5fC and 5-carboxycytosine (5caC), which were found at levels below 0.002% (or 20 ppm) of all Cs in the genomic DNA of mouse embryonic stem (mES) cells and several adult mouse tissues [7] [8] [9] .
One proposed role for these oxidised cytosine bases is to serve as intermediates of enzyme-mediated DNA demethylation initiated by oxidation of 5mC 10, 11 . Indeed, thymine-DNA glycosylase (TDG) can selectively recognise and excise 5fC and 5caC from the genome and trigger a repair process, which can lead to restoring unmodified C 7, 12 . Moreover, mES cells lacking TDG show increased levels of 5fC and 5caC, suggesting that a part of these modifications is constantly being removed from the genome of mES cells 7, 12 . On the other hand, we recently demonstrated that 5hmC is a predominantly stable modification in mammalian DNA, especially in the adult mouse brain where 5hmC is most abundant 6 . Herein we investigate the temporal dynamics of 5fC in genomic DNA in vivo to consider whether this 3 rare modification can be stable, rather than an active demethylation intermediate (Fig. 1a) .
We first analysed global levels of all cytosine modifications in the genomic DNA of C57BL/6 mouse tissues to see whether we can detect and quantify 5fC, and identify a relationship between its levels and those of its precursors 5mC and 5hmC or its metabolite 5caC. We included a range of postnatal tissues from newborn (1 d old), adolescent (21 d old) and adult (15 w old) mice, as their genomic DNA is known to have different levels of 5hmC depending on the overall proliferation rate (and therefore the age) of the tissue 6 . We also included C57BL/6 embryos at 11.5 d post-fertilisation as this is the lethal age for mice lacking TDG 13, 14 , and mES cells derived from the same strain were added for comparison. To achieve quantification of the rare modifications (5fC and 5caC) with the highest possible sensitivity and accuracy, we employed a nano high-performance liquid chromatographytandem high-resolution mass spectrometry (nanoHPLC-MS/HRMS) method, which is able to resolve genuine rare modified bases (5fC and 5caC) from potential impurities of the same nominal mass and retention time, and can detect down to 0.1 ppm of total cytosines in as little as 100 ng of digested genomic DNA. In addition, the use of isotopically labelled internal standards (IS) of C, 5mC and 5hmC substantially improved the quality of the measurements, ensured excellent reproducibility between technical replicates and excluded spontaneous oxidation of 5hmC as the source of 5fC or 5caC. Fig. 6 ) and their levels were in good agreement with available published data 5, 6, 8, 9 . While 5mC levels show a relatively uniform distribution between tissues, global 5hmC content is highly correlated to the proportion of proliferating cells in the tissue as we have shown previously 6 . We found 5fC to be also present in all studied tissues at levels ranging between 0.2 ppm and 15 ppm of all cytosines ( Fig.   1b and Supplementary Fig. 6 ). Notably, 5caC was not detected in any postnatal tissues from C57BL/6 mice, even in those with high 5fC content, but several tissues from C57BL/6 embryos ( Fig. 1b) and adult (12 w old) CD1 mice ( Supplementary Fig. 7 ) contained up to 2 ppm of this rare DNA base modification. Overall, we found no correlation between the levels of 5fC and the levels of its precursors 5mC or 5hmC ( Supplementary Fig. 8 ), nor did we find any clear pattern of DNA modification changes as the tissues age. They can retain the levels of 5fC while gaining 5hmC (e.g. brain), lose 5fC while retaining the levels of 5hmC (e.g. heart), or even lose 5fC while gaining 5hmC (e.g. liver) (Figs. 1c-e) . We found that DNA from mES cells lacking all three TET enzymes (TET triple-knockout (TET-TKO)) 15 contains no detectable 5hmC, 5fC or 5caC ( Fig. 1a and Supplementary Fig. 6 ), confirming that 5hmC is the only source of 5fC and 5caC in mES cell DNA. Although we have no measure of tissue-specific susceptibility to oxidation (such as the quantity of the oxidative lesion 8-oxoguanine), the lack of correlation between global levels of 5hmC and 5fC ( Supplementary Fig. 8 ) together with the lack of positional overlap between 5hmC and 5fC in mES cells 16, 17 strongly suggest that 5fC and 5caC are not generated by spontaneous oxidation of 5hmC and 5fC. (Fig. 1a) . The labelling ratios (e.g. % 5fC[+2] over total 5fC) change according to the dynamics and half-life of the given modification in the genomic DNA. For example, a modification that is quickly turning over in DNA would show a high labelling ratio, whereas a very stable modification would show no labelling in non-proliferating cells or tissues. The maximum obtainable ratio also depends on the activity of other biosynthetic pathways feeding into the one carbon metabolism. The labelling ratios can be determined very accurately for each modified cytosine using LC-MS/HRMS due to unique masses of the labelled base fragments (Supplementary Fig. 8 ).
We first cultured mES cells in the labelled ([methyl-
13
CD 3 ] L-methionine) media for 8 days, and found that the labelling ratio of 5fC increases much slower than that of 5mC and 5hmC. This indicates either a substantial time lag in making 5fC from newly formed 5hmC, or presence of a population of slower or non-dividing (unlabelled) cells with higher global levels of 5fC compared to the fast dividing (labelled) population of mES cells (Fig. 2a) .
We then analysed genomic DNA from C57BL/6 mice fed with a diet where all L-methionine was replaced with [methyl-
CD 3 ] L-methionine. To gain information about 5fC in developing tissues, we fed a pregnant female starting 6 from 7 d before birth, and kept the family for 6 more days on the labelled diet (the 6 d-old pups were therefore labelled for 13 d when harvested). The genomic DNA in tissues such as kidney or colon showed uniform labelling of around 30% for all detectable modifications (5mC, 5hmC and 5fC) (Fig. 2b) .
However, brain tissue from the same pups showed much less 5hmC already showed a higher 5fC labelling in the brain, but the ratio was still lower than those of 5mC and 5hmC (27% vs. 44% and 42.5%, respectively) ( Fig.   2b) . During the gestation period, the labelling ratio of the methionine pool in the pregnant female was still increasing and therefore this observation is consistent with 5fC being more abundant on the older or slower proliferating DNA as concluded above. Proliferating tissues from adult mice (e.g. spleen)
showed a similar trend where the 5fC labelling ratio was always smaller than that of 5mC or 5hmC, even in animals labelled for as long as 4 months (117 d) (Fig. 2c) . This effect is best explained by 5fC being mostly stable, and again by the presence of non-dividing (unlabelled) cells alongside a population of proliferating (labelled) cells that have lower global 5fC levels than the non-dividing cells.
Finally, in the mostly non-dividing adult brain where only 1.3% and 3.7% of 5mC becomes labelled during the 117-d feeding period, there was no detectable labelled 5fC. Again, this is not due to a lack of an intracellular pool of [methyl- 13 CD 3 ] SAM, as we could measure more than 50% [methyl- 13 CD 3 ] 7 5mC in RNA in adult brain and cerebellum (Fig. 2d) . If 5fC was a short-lived DNA modification and was constantly being turned over, its labelling ratio would be close to the labelling ratio of intracellular SAM and 5mC in RNA. If 5fC was short-lived and only produced from pre-existing unlabelled 5hmC in the adult brain, the levels of 5hmC would be depleted over time, which is not consistent with the high levels of 5hmC in this tissue and is the opposite of what has been described for ageing brain 18 . Therefore, the lack of 5fC labelling in the adult brain means that this modified base must be stable in the genome as opposed to generally acting as a dynamic intermediate of active
In summary, we present the first direct evidence that 5fC (derived from mC by TET-mediated oxidation) can be a stable DNA modification in vivo, and provide quantitative measurements of the levels of all modified cytosines in mouse tissues across several developmental stages. 5fC levels do not correlate with those of its precursors 5mC and 5hmC, its metabolite 5caC or with age of the individual. Whilst there is precedent for removal of 5fC and 5caC from the genome (e.g. in mES cells), probably in the process of active DNA demethylation 7, 12 , our findings suggest that the bulk of 5fC can be stable.
5fC has been identified as having more protein binders than 5mC or 5hmC 19,20 and having a distinct genomic profile from 5mC, 5hmC or 5caC at single-base resolution 12, 16, 17, [21] [22] [23] . Moreover, 5fC has recently been shown to alter the structure of the DNA double helix 24 . We therefore conclude that such stably 5fC-modified DNA could have profound consequences for the regulation of gene expression that may be distinct to those caused by the presence of 5mC and 5hmC. However, direct evidence regarding the biological function of 5fC remains to be demonstrated.
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Additional information
Supplementary Figures 1-9 supplemented with 400 μg/ml proteinase K (Invitrogen), and were incubated at 55°C overnight. DNA was purified using phenol:chloroform:isoamyl alcohol Global levels of 5fC and 5caC in genomic DNA from mouse embryos (E11.5).
Shown are mean ± SEM of 3 animals. Each sample was analysed in technical duplicate and the mean value was used. (c, d, e) Changes of global 5fC, 5mC
and 5hmC levels during development in selected C57BL/6 mouse tissues (further data in Supplementary Fig. 6 ). Shown are mean ± SEM of 3 embryos (E11.5) (data from replicates from individual mice, and total labelling time is shown in brackets.
The absence of 5fC[+2] in the brain (d) where 5fC is most abundant (see Fig.   1 and Supplementary Fig. 6 ) indicates minimal or no further generation of 5fC once placed in post-mitotic tissues. Moreover, if 5fC was involved in cycles of methylation and demethylation, its labelling ratio would be similar to that of 5mC in RNA (d).
